PhRMA Meets With Indian Officials To Discuss Compulsory Licensing
Executive Summary
Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India’s move toward compulsory licensing.
You may also be interested in...
Stage Set For India To Frame Compulsory Licensing Provisions As Contrasting Groups Make Their Case
The Department of Industrial Policy and Promotion is analyzing and interpreting comments on a contentious subject that has kept Indian and multinational drug firms bitterly divided for more than five years, while forcing the government into a dilemma over an acceptable policy.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.